Alice Y Y Cheng. Circulation 2021
Times Cited: 3
Times Cited: 3
Times Cited
Times Co-cited
Similarity
Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.
Chintan V Dave, Seoyoung C Kim, Allison B Goldfine, Robert J Glynn, Angela Tong, Elisabetta Patorno. Circulation 2021
Chintan V Dave, Seoyoung C Kim, Allison B Goldfine, Robert J Glynn, Angela Tong, Elisabetta Patorno. Circulation 2021
66
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
66
Meta-analyses of Results From Randomized Outcome Trials Comparing Cardiovascular Effects of SGLT2is and GLP-1RAs in Asian Versus White Patients With and Without Type 2 Diabetes.
Matthew M Y Lee, Nazim Ghouri, Darren K McGuire, Martin K Rutter, Naveed Sattar. Diabetes Care 2021
Matthew M Y Lee, Nazim Ghouri, Darren K McGuire, Martin K Rutter, Naveed Sattar. Diabetes Care 2021
33
Associations of progression to diabetes and regression to normal glucose tolerance with development of cardiovascular and microvascular disease among people with impaired glucose tolerance: a secondary analysis of the 30 year Da Qing Diabetes Prevention Outcome Study.
Yanyan Chen, Ping Zhang, Jinping Wang, Qiuhong Gong, Yali An, Xin Qian, Bo Zhang, Hui Li, Edward W Gregg, Peter H Bennett,[...]. Diabetologia 2021
Yanyan Chen, Ping Zhang, Jinping Wang, Qiuhong Gong, Yali An, Xin Qian, Bo Zhang, Hui Li, Edward W Gregg, Peter H Bennett,[...]. Diabetologia 2021
33
Years of potential life lost in pre-diabetes and diabetes mellitus: data from a 40-year follow-up of the Israel study on Glucose intolerance, Obesity and Hypertension.
Micha Rapoport, Angela Chetrit, Dror Cantrell, Ilya Novikov, Jesse Roth, Rachel Dankner. BMJ Open Diabetes Res Care 2021
Micha Rapoport, Angela Chetrit, Dror Cantrell, Ilya Novikov, Jesse Roth, Rachel Dankner. BMJ Open Diabetes Res Care 2021
33
Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis.
Rebuma Belete, Zerihun Ataro, Ahmedmenewer Abdu, Merga Sheleme. Diabetol Metab Syndr 2021
Rebuma Belete, Zerihun Ataro, Ahmedmenewer Abdu, Merga Sheleme. Diabetol Metab Syndr 2021
33
The SimpliciT1 Study: A Randomized, Double-Blind, Placebo-Controlled Phase 1b/2 Adaptive Study of TTP399, a Hepatoselective Glucokinase Activator, for Adjunctive Treatment of Type 1 Diabetes.
Klara R Klein, Jennifer L R Freeman, Imogene Dunn, Chris Dvergsten, M Sue Kirkman, John B Buse, Carmen Valcarce. Diabetes Care 2021
Klara R Klein, Jennifer L R Freeman, Imogene Dunn, Chris Dvergsten, M Sue Kirkman, John B Buse, Carmen Valcarce. Diabetes Care 2021
33
Trends in the incidence of diagnosed diabetes: a multicountry analysis of aggregate data from 22 million diagnoses in high-income and middle-income settings.
Dianna J Magliano, Lei Chen, Rakibul M Islam, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Linda J Andes, Ran Balicer, Marta Baviera, Elise Boersma-van Dam,[...]. Lancet Diabetes Endocrinol 2021
Dianna J Magliano, Lei Chen, Rakibul M Islam, Bendix Carstensen, Edward W Gregg, Meda E Pavkov, Linda J Andes, Ran Balicer, Marta Baviera, Elise Boersma-van Dam,[...]. Lancet Diabetes Endocrinol 2021
33
Quantifying the Sex-Race/Ethnicity-Specific Burden of Obesity on Incident Diabetes Mellitus in the United States, 2001 to 2016: MESA and NHANES.
Natalie A Cameron, Lucia C Petito, Megan McCabe, Norrina B Allen, Matthew J O'Brien, Mercedes R Carnethon, Sadiya S Khan. J Am Heart Assoc 2021
Natalie A Cameron, Lucia C Petito, Megan McCabe, Norrina B Allen, Matthew J O'Brien, Mercedes R Carnethon, Sadiya S Khan. J Am Heart Assoc 2021
33
GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis.
Thomas Karagiannis, Apostolos Tsapas, Eleni Athanasiadou, Ioannis Avgerinos, Aris Liakos, David R Matthews, Eleni Bekiari. Diabetes Res Clin Pract 2021
Thomas Karagiannis, Apostolos Tsapas, Eleni Athanasiadou, Ioannis Avgerinos, Aris Liakos, David R Matthews, Eleni Bekiari. Diabetes Res Clin Pract 2021
33
Thirty-Year Trends in Complications in U.S. Adults With Newly Diagnosed Type 2 Diabetes.
Michael Fang, Elizabeth Selvin. Diabetes Care 2021
Michael Fang, Elizabeth Selvin. Diabetes Care 2021
33
Risk Factors for Longitudinal Resting Heart Rate and Its Associations With Cardiovascular Outcomes in the DCCT/EDIC Study.
Sareh Keshavarzi, Barbara H Braffett, Rodica Pop-Busui, Trevor J Orchard, Elsayed Z Soliman, Gayle M Lorenzi, Annette Barnie, Amy B Karger, Rose A Gubitosi-Klug, Samuel Dagogo-Jack,[...]. Diabetes Care 2021
Sareh Keshavarzi, Barbara H Braffett, Rodica Pop-Busui, Trevor J Orchard, Elsayed Z Soliman, Gayle M Lorenzi, Annette Barnie, Amy B Karger, Rose A Gubitosi-Klug, Samuel Dagogo-Jack,[...]. Diabetes Care 2021
100
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
33
Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
33
GLP-1 receptor agonists and cardiovascular outcome trials: An update.
Eirini Andrikou, Costas Tsioufis, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios Tousoulis, Nikolaos Papanas. Hellenic J Cardiol 2019
Eirini Andrikou, Costas Tsioufis, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios Tousoulis, Nikolaos Papanas. Hellenic J Cardiol 2019
33
Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add-on to sodium-glucose co-transporter-2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes.
Athena Philis-Tsimikas, Liana K Billings, Robert Busch, Cristobal Morales Portillo, Rakesh Sahay, Natalie Halladin, Sarah Eggert, Kamilla Begtrup, Stewart Harris. Diabetes Obes Metab 2019
Athena Philis-Tsimikas, Liana K Billings, Robert Busch, Cristobal Morales Portillo, Rakesh Sahay, Natalie Halladin, Sarah Eggert, Kamilla Begtrup, Stewart Harris. Diabetes Obes Metab 2019
33
Sulfonylureas and the Risks of Cardiovascular Events and Death: A Methodological Meta-Regression Analysis of the Observational Studies.
Laurent Azoulay, Samy Suissa. Diabetes Care 2017
Laurent Azoulay, Samy Suissa. Diabetes Care 2017
33
Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
André J Scheen. Diabetes Res Clin Pract 2018
André J Scheen. Diabetes Res Clin Pract 2018
33
Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
Tina Vilsbøll, Mikkel Christensen, Anders E Junker, Filip K Knop, Lise Lotte Gluud. BMJ 2012
33
Effects of intensive glucose lowering in type 2 diabetes.
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
Hertzel C Gerstein, Michael E Miller, Robert P Byington, David C Goff, J Thomas Bigger, John B Buse, William C Cushman, Saul Genuth, Faramarz Ismail-Beigi, Richard H Grimm,[...]. N Engl J Med 2008
33
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
Thomas A Zelniker, Stephen D Wiviott, Itamar Raz, KyungAh Im, Erica L Goodrich, Remo H M Furtado, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn,[...]. Circulation 2019
33
A Verdict for Glimepiride: Effective and Not Guilty of Cardiovascular Harm.
Matthew C Riddle. Diabetes Care 2019
Matthew C Riddle. Diabetes Care 2019
33
Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
B Willms, J Werner, J J Holst, C Orskov, W Creutzfeldt, M A Nauck. J Clin Endocrinol Metab 1996
B Willms, J Werner, J J Holst, C Orskov, W Creutzfeldt, M A Nauck. J Clin Endocrinol Metab 1996
33
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
Adrian F Hernandez, Jennifer B Green, Salim Janmohamed, Ralph B D'Agostino, Christopher B Granger, Nigel P Jones, Lawrence A Leiter, Anne E Rosenberg, Kristina N Sigmon, Matthew C Somerville,[...]. Lancet 2018
33
Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial.
Marcel H A Muskiet, Lennart Tonneijck, Yao Huang, Minzhi Liu, Aramesh Saremi, Hiddo J L Heerspink, Daniël H van Raalte. Lancet Diabetes Endocrinol 2018
Marcel H A Muskiet, Lennart Tonneijck, Yao Huang, Minzhi Liu, Aramesh Saremi, Hiddo J L Heerspink, Daniël H van Raalte. Lancet Diabetes Endocrinol 2018
33
The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion.
Patrick E MacDonald, Wasim El-Kholy, Michael J Riedel, Anne Marie F Salapatek, Peter E Light, Michael B Wheeler. Diabetes 2002
Patrick E MacDonald, Wasim El-Kholy, Michael J Riedel, Anne Marie F Salapatek, Peter E Light, Michael B Wheeler. Diabetes 2002
33
The SGLT2 Inhibitor Dapagliflozin Significantly Improves the Peripheral Microvascular Endothelial Function in Patients with Uncontrolled Type 2 Diabetes Mellitus.
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara,[...]. Intern Med 2018
Seigo Sugiyama, Hideaki Jinnouchi, Noboru Kurinami, Kunio Hieshima, Akira Yoshida, Katsunori Jinnouchi, Hiroyuki Nishimura, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara,[...]. Intern Med 2018
33
Type 2 diabetes mellitus: a review of current trends.
Abdulfatai B Olokoba, Olusegun A Obateru, Lateefat B Olokoba. Oman Med J 2012
Abdulfatai B Olokoba, Olusegun A Obateru, Lateefat B Olokoba. Oman Med J 2012
33
Glucose control and vascular complications in veterans with type 2 diabetes.
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
William Duckworth, Carlos Abraira, Thomas Moritz, Domenic Reda, Nicholas Emanuele, Peter D Reaven, Franklin J Zieve, Jennifer Marks, Stephen N Davis, Rodney Hayward,[...]. N Engl J Med 2009
33
Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: A meta-analysis.
Marco Castellana, Angelo Cignarelli, Francesco Brescia, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino. Sci Rep 2019
Marco Castellana, Angelo Cignarelli, Francesco Brescia, Sebastio Perrini, Annalisa Natalicchio, Luigi Laviola, Francesco Giorgino. Sci Rep 2019
33
Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists.
Annachiara Uccellatore, Stefano Genovese, Ilaria Dicembrini, Edoardo Mannucci, Antonio Ceriello. Diabetes Ther 2015
Annachiara Uccellatore, Stefano Genovese, Ilaria Dicembrini, Edoardo Mannucci, Antonio Ceriello. Diabetes Ther 2015
33
Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors.
Vasiliki Bistola, Vaia Lambadiari, George Dimitriadis, Ioannis Ioannidis, Konstantinos Makrilakis, Nikolaos Tentolouris, Apostolos Tsapas, John Parissis. Heart Fail Rev 2018
Vasiliki Bistola, Vaia Lambadiari, George Dimitriadis, Ioannis Ioannidis, Konstantinos Makrilakis, Nikolaos Tentolouris, Apostolos Tsapas, John Parissis. Heart Fail Rev 2018
33
2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
Francesco Cosentino, Peter J Grant, Victor Aboyans, Clifford J Bailey, Antonio Ceriello, Victoria Delgado, Massimo Federici, Gerasimos Filippatos, Diederick E Grobbee, Tina Birgitte Hansen,[...]. Eur Heart J 2020
33
Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose.
S J FARBER, E Y BERGER, D P EARLE. J Clin Invest 1951
S J FARBER, E Y BERGER, D P EARLE. J Clin Invest 1951
33
Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
Milton Packer. Circulation 2017
Milton Packer. Circulation 2017
33
Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults.
J van Can, B Sloth, C B Jensen, A Flint, E E Blaak, W H M Saris. Int J Obes (Lond) 2014
J van Can, B Sloth, C B Jensen, A Flint, E E Blaak, W H M Saris. Int J Obes (Lond) 2014
33
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
Anushka Patel, Stephen MacMahon, John Chalmers, Bruce Neal, Laurent Billot, Mark Woodward, Michel Marre, Mark Cooper, Paul Glasziou, Diederick Grobbee,[...]. N Engl J Med 2008
33
The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure.
Merlin C Thomas, David Z I Cherney. Diabetologia 2018
Merlin C Thomas, David Z I Cherney. Diabetologia 2018
33
Cardiovascular disease and type 2 diabetes mellitus: regulating glucose and regulating drugs.
M Odette Gore, Darren K McGuire. Curr Cardiol Rep 2009
M Odette Gore, Darren K McGuire. Curr Cardiol Rep 2009
33
Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
Bernhard Ludvik, Juan P Frías, Francisco J Tinahones, Julio Wainstein, Honghua Jiang, Kenneth E Robertson, Luis-Emilio García-Pérez, D Bradley Woodward, Zvonko Milicevic. Lancet Diabetes Endocrinol 2018
Bernhard Ludvik, Juan P Frías, Francisco J Tinahones, Julio Wainstein, Honghua Jiang, Kenneth E Robertson, Luis-Emilio García-Pérez, D Bradley Woodward, Zvonko Milicevic. Lancet Diabetes Endocrinol 2018
33
Glucagon-like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter Inhibitors for Treatment of T2DM.
Alexis McKee, Ali Al-Khazaali, Stewart G Albert. J Endocr Soc 2020
Alexis McKee, Ali Al-Khazaali, Stewart G Albert. J Endocr Soc 2020
33
Adverse Effects of GLP-1 Receptor Agonists.
Theodosios D Filippatos, Thalia V Panagiotopoulou, Moses S Elisaf. Rev Diabet Stud 2014
Theodosios D Filippatos, Thalia V Panagiotopoulou, Moses S Elisaf. Rev Diabet Stud 2014
33
10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2019.
. Diabetes Care 2019
. Diabetes Care 2019
33
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
33
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden,[...]. N Engl J Med 2021
John P H Wilding, Rachel L Batterham, Salvatore Calanna, Melanie Davies, Luc F Van Gaal, Ildiko Lingvay, Barbara M McGowan, Julio Rosenstock, Marie T D Tran, Thomas A Wadden,[...]. N Engl J Med 2021
33
Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis.
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
A Liakos, T Karagiannis, E Athanasiadou, M Sarigianni, M Mainou, K Papatheodorou, E Bekiari, A Tsapas. Diabetes Obes Metab 2014
33
Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria.
Suzanne Geerlings, Vivian Fonseca, David Castro-Diaz, James List, Shamik Parikh. Diabetes Res Clin Pract 2014
Suzanne Geerlings, Vivian Fonseca, David Castro-Diaz, James List, Shamik Parikh. Diabetes Res Clin Pract 2014
33
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
33
Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: a network meta-analysis.
Elizabeth S Mearns, Diana M Sobieraj, C Michael White, Whitney J Saulsberry, Christine G Kohn, Yunes Doleh, Eric Zaccaro, Craig I Coleman. PLoS One 2015
Elizabeth S Mearns, Diana M Sobieraj, C Michael White, Whitney J Saulsberry, Christine G Kohn, Yunes Doleh, Eric Zaccaro, Craig I Coleman. PLoS One 2015
33
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.